Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure
| Autor: | Koki Nakamura, Emi Nakata, Kazuhiro Yamamoto, Kenkichi Sugiura, Yuko Miyata, Masunori Matsuzaki, Hiroyuki Tsutsui, Masafumi Yano |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cardiac function curve Left ventricular ejection fraction medicine.medical_specialty Time Factors Tetrazoles Severity of Illness Index New york heart association Asian People Internal medicine Natriuretic Peptide Brain Humans Medicine cardiovascular diseases Aged Aged 80 and over Heart Failure Ejection fraction Candesartan business.industry Biphenyl Compounds Stroke Volume Middle Aged Brain natriuretic peptide medicine.disease Heart failure Chronic Disease Heart Function Tests Angiotensin II receptor blocker cardiovascular system Cardiology Benzimidazoles Female Cardiology and Cardiovascular Medicine business Angiotensin II Type 1 Receptor Blockers Biomarkers circulatory and respiratory physiology medicine.drug |
| Zdroj: | Journal of Cardiology. 61:267-274 |
| ISSN: | 0914-5087 |
| DOI: | 10.1016/j.jjcc.2012.12.004 |
| Popis: | Background Chronic heart failure (CHF) is an increasingly common cardiovascular disease despite recent advances in its diagnosis and management. Methods and results A multicenter, open-label study was designed to assess the efficacy and safety of 60-week treatment with candesartan in Japanese patients with mild to moderate CHF. Primary efficacy endpoints were changes from baseline in plasma brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), end-diastolic dimension, and New York Heart Association (NYHA) functional class. Two hundred and eighty-nine eligible patients were divided into 2 groups based on the daily dose at the end of treatment: high-dose (HD, 8 mg, N = 170) and low-dose (LD, 2 or 4 mg, N = 119). Neither plasma BNP levels nor LVEF changed from the baseline to the end of treatment in the LD group, whereas BNP significantly improved from 61.6 to 50.1 pg/mL (p = 0.0005) and LVEF from 57.2 to 60.1% (p = 0.0005) in the HD group. The changes in NYHA functional class were comparable between groups: 21.2% improved and 76.3% unchanged in the LD group and 20.6% improved and 79.4% unchanged in the HD group. No safety concerns were observed in either group. Conclusions HD candesartan was more effective in improving plasma BNP levels and cardiac function than LD in Japanese CHF patients. Both LD and HD candesartan were well tolerated in CHF patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect